Policy and patient advocacy groups are calling on the Institute for Clinical and Economic Review to rerun its analysis on the cost-effectiveness of three drugs to treat acute migraines, using ICER’s updated framework that considers societal factors. The advocacy groups expect the cost-effectiveness rating of the three drugs would increase further using that framework. On Tuesday (Feb. 25), the Institute for Clinical and Economic Review reversed direction and decided that a pair of drugs for treating migraines are more useful...